Marizomib
Drug
Celgene Corporation
Total Payments
$2.2M
Transactions
37
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $657,798 | 21 | 8 |
| 2018 | $1.6M | 16 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 37 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MRZ-112 - PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB COMBINED WITH TEMOZOLOMIDE AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA | Celgene Corporation | $1.0M | 0 |
| MRZ-108 - MRZ-108 Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of MRZ & Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Singl | Celgene Corporation | $497,056 | 2 |
| PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB COMBINED WITH TEMOZOLOMIDE AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (MRZ-112) | Celgene Corporation | $351,184 | 6 |
| MRZ-108 Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of MRZ & Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent MRZ & Combination MRZ & Bevacizumab (CA070-P01) (MRZ-108) | Celgene Corporation | $306,594 | 5 |
| MRZ-107 NPI-0052-107) - A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107) | Celgene Corporation | $24,252 | 0 |
| NPI-005-001 - NPI-005-001 | Celgene Corporation | $12,537 | 0 |
| MRZ-CL-BRAIN-NCI-12815 - Phase II Clinical Trial of Marizomib in Patients with Recurrent Ependymomas | Celgene Corporation | $7,040 | 0 |
| MRZ-108-Monotheraphy - Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data | Celgene Corporation | $4,105 | 0 |
| Phase II Clinical Trial of Marizomib in Patients with Recurrent Ependymomas (MRZ-CL-BRAIN-NCI-12815) | Celgene Corporation | $20.04 | 0 |
Top Doctors Receiving Payments for Marizomib
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Evanston, IL | $2.2M | 24 |
| , MD | Neurology | Orange, CA | $7,216 | 3 |
| , M.D | Neurology | Durham, NC | $4,486 | 2 |
| , MD PHD | Neurology | Santa Monica, CA | $4,486 | 2 |
| , M.D | Neurology | New York, NY | $2,866 | 1 |
| , MD | Psychiatry | Corona, CA | $2,730 | 2 |
| , MD | Neurology | Chicago, IL | $1,620 | 1 |
| , M.D., PH.D | Neurology | Los Angeles, CA | $1,620 | 1 |
| , M.D | Neurological Surgery | Hershey, PA | $1,620 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $2.2M
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 8
- Transactions 37
About Marizomib
Marizomib is a drug associated with $2.2M in payments to 8 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $657,798 was paid across 21 transactions to 8 doctors.
The most common payment nature for Marizomib is "Unspecified" ($2.2M, 100.0% of total).
Marizomib is associated with 9 research studies, including "MRZ-112 - PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB COMBINED WITH TEMOZOLOMIDE AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA" ($1.0M).